Regenexx Knee Osteoarthritis Stem Cell Treatment Study Results

Regenexx Knee Osteoarthritis Stem Cell Treatment Study Results

Regenexx® Announces Positive Results From Largest Knee Osteoarthritis Stem Cell Treatment Study to Date

Denver, CO September 9, 2015 — Regenexx®, a nationwide network of doctors specializing in regenerative medicine and advanced interventional orthopedic techniques, today announced the results of a peer-reviewed research study of 840 patients treated for knee osteoarthritis. All patients were treated using precise imaging guidance and the patented Regenexx protocol, which obtains stem cells from the patient’s own bone marrow.

“We’re proud to say that this study represents the largest published human experience with stem cell injections to treat knee arthritis to date”, stated Christopher Centeno, M.D., the company’s CEO. “No group has published more data on same day stem cell procedures to treat common orthopedic conditions without surgery”, added Centeno.

The research study on knee arthritis examined the efficacy and safety of bone marrow and bone marrow plus fat stem cell injections. Most of the study patients were knee replacement candidates. Many patients in the study were able to avoid knee replacement. Self-rated functional and pain scores all showed statistically significant positive changes from baseline in both treatment groups. The study concluded that there was no advantage of adding fat to the joint over just bone marrow stem cells. Safety in both groups was excellent compared to knee replacement.

It’s important to note that these studies represent data collected in the Regenexx registry as patients are treated and that this data wasn’t collected as part of a randomized controlled trial (RCT) of the type commonly used in drug studies. The company has 3 such RCTs that it has funded. One knee osteoarthritis study being conducted in Chicago has completed enrollment, while the other studies for shoulder rotator cuff tears and ACL tears are open and still recruiting in Colorado.

About Regenexx

The Regenexx® Procedures are the nation’s most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient’s own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.

For more information on Regenexx, please visit: https://regenexx.com

Full text of the study: https://regenexx.com/wp-content/uploads/2015/09/370621-1.pdf

Learn More About Regenexx® Procedures
Request a digital booklet and more information to learn about alternatives to orthopedic surgery and the Regenexx patient experience.
We do not sell, or share your information to third party vendors. By submitting the form you agree that you've read and consent to our Privacy Policy.
Chris Centeno, MD is a specialist in regenerative medicine and the new field of Interventional Orthopedics. Centeno pioneered orthopedic stem cell procedures in 2005 and is responsible for a large amount of the published research on stem cell use for orthopedic applications. View Profile

If you have questions or comments about this blog post, please email us at [email protected]

NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.

TO TOP